Summary & Overview
HCPCS Q5118: Bevacizumab-bvzr (Zirabev) 10 mg Injection
HCPCS Level II code Q5118 denotes a 10 mg unit of bevacizumab-bvzr (Zirabev), a biosimilar to bevacizumab used as an intravenous oncologic biologic. Nationally, biosimilar billing codes like Q5118 matter for cost management, formulary placement, and claims processing because they enable specific identification of biosimilar agents versus reference biologics. Payors use these codes to track utilization, apply coverage policies, and manage reimbursement for high-cost injectable therapies.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what Q5118 represents clinically and operationally, typical sites of service where the product is administered, and the practical implications for payers and billing workflows. The publication covers benchmarks for unitization and billing practices, relevant policy and coding updates affecting biosimilars, and clinical context for use of bevacizumab biosimilars in oncology infusion settings. Information not supplied in the input — such as associated taxonomies, specific ICD-10 diagnoses, and payer-specific coverage rules — is identified as unavailable to maintain accuracy.
Billing Code Overview
HCPCS Level II code Q5118 describes injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg. This code represents a billed unit for the biosimilar monoclonal antibody bevacizumab-bvzr (brand name Zirabev) supplied for parenteral administration.
-
Service type: Intravenous injectable biologic therapy
-
Typical site of service: Hospital outpatient department, physician office infusion suite, or ambulatory infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old with metastatic colorectal cancer receiving systemic therapy. The oncology team orders an intravenous dose of bevacizumab-bvzr (Q5118) as part of a chemotherapy regimen to inhibit angiogenesis. The patient arrives to an outpatient infusion center or hospital outpatient department for pre-infusion assessment, including vitals, review of recent labs (especially blood pressure, proteinuria/urinalysis, and renal function), and confirmation of the treatment plan. A registered nurse establishes IV access, verifies the dispensed Q5118 vial strength and dose against the physician order and patient weight, and prepares the infusion according to facility protocols. The infusion is administered over the recommended infusion time with monitoring for infusion reactions and blood pressure changes. Post-infusion, the patient is observed for a short period, educated about signs of bleeding, hypertension, thromboembolic events, and wound-healing complications, and discharged with follow-up oncology appointments. Typical sites of service are an outpatient infusion center, hospital outpatient department, or physician office infusion suite.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient | When part of the single-use vial is wasted and payer requires reporting of discarded medication |